2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Infusion, Non-Biological Therapies, Chemotherapy, Pharmacology, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

1541 Frontline CD19 CAR T-cell consolidation in newly diagnosed Ph+ acute lymphoblastic leukemia: A transplantation-free real-world study

Yiyan Zhu, Wenzhi CAI, MD2, Jun Zhang3, Xinyue Zhang4, Dan Liu, MD5, Hongying Chao6, Depei Wu Sr, MD7, Suning Chen8
1 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
2 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
3 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
4 Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
5 Soochow Hopes Hematonosis Hospital, Suzhou, Jiangsu, China
6 Affiliated Changzhou Second Hospital of Nanjing Medical University, Changzhou, Jiangsu, China
7 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China
8 The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center of Hematologic Diseases, Suzhou, China

Introduction:

Tyrosine kinase inhibitors and blinatumomab have improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), yet persistent measurable residual disease (MRD) and relapse continue to limit transplantation-free treatment. Whether CD19 chimeric antigen receptor (CAR) T-cell consolidation during first complete remission (CR1) can provide durable disease control without allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains uncertain. We evaluated the effectiveness and safety of this strategy.

Methods:

In this multicenter retrospective real-world study, 574 patients with de novo Ph+ ALL treated between January 2016 and December 2025 were screened. The primary CAR T-cell cohort comprised 68 patients who achieved CR1, received frontline autologous CD19 CAR T-cell consolidation, and underwent no subsequent allo-HSCT. We assessed MRD by flow cytometry (FCM), BCR::ABL1 quantitative polymerase chain reaction (qPCR), and immunoglobulin/T-cell receptor gene rearrangement-based next-generation sequencing (IG/TR NGS) when paired samples were available. CAR T-cell expansion, relapse, survival, and adverse events were evaluated. Event-free survival (EFS) and overall survival (OS) were calculated from CAR T-cell infusion. For an exploratory, unadjusted comparison, EFS and OS were compared by log-rank testing with those of 34 contemporaneous patients who received frontline blinatumomab-based consolidation at the same participating centers.

Results:

The median age was 45 years (range, 17–65); 16 patients (23.5%) had extramedullary disease at diagnosis, and 42 (61.8%) remained in CR without a major molecular response after induction. Following CAR T-cell infusion, FCM-MRD negativity increased from 66.2% (45/68) to 76.5% (52/68), with 16 of 23 (69.6%) pre-infusion FCM-MRD-positive patients converting to negative. The complete molecular response (CMR) rate increased from 51.5% (35/68) to 77.9% (53/68), with 20 of 33 (60.6%) patients without pre-infusion CMR achieving CMR. Among 12 patients with paired IG/TR NGS-MRD data, MRD negativity increased from 66.7% (8/12) to 91.7% (11/12). The median peak CAR transgene copy number was 7.23 × 104 copies/μg DNA at a median of 9 days after infusion. At a median follow-up of 37.2 months, 3-year EFS, OS, and cumulative incidence of relapse were 87.7% (95% CI, 74.4–94.3%), 91.4% (95% CI, 78.4–96.8%), and 10.7% (95% CI, 1.7–19.8%), respectively. In the contemporaneous blinatumomab cohort (n = 34; median follow-up, 13.8 months), 1-year EFS and OS were 94.1% and 96.7%, respectively, versus 96.5% and 98.4% in the CAR T-cell cohort; survival curves did not differ significantly (log-rank P = 0.081 for EFS and P = 0.510 for OS). Seven patients (10.3%) in the CAR T-cell cohort relapsed, with no central nervous system (CNS) or other extramedullary relapses; five patients (14.7%) in the blinatumomab cohort relapsed, including one CNS and two non-CNS extramedullary relapses. In the CAR T-cell cohort, cytokine release syndrome (CRS) occurred in 28 patients (41.2%), all grade 1–2; no immune effector cell-associated neurotoxicity syndrome (ICANS) occurred.

Conclusions:

In this multicenter cohort, frontline CD19 CAR T-cell consolidation during CR1 was associated with substantial MRD deepening and durable disease control without subsequent allo-HSCT, with no grade ≥3 CRS and no ICANS. Although no significant survival difference was observed in the exploratory comparison with a smaller blinatumomab cohort with shorter follow-up, these findings support prospective comparative evaluation of CAR T-cell consolidation as a transplantation-free post-remission strategy for Ph+ ALL.

Yiyan Zhu: No relevant conflicts of interest to declare.